Autopsy report · NCT03980730

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

“for business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 7 months before it stopped.
• 43 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

vTv Therapeutics

Sponsor type

Industry

Conditions

Alzheimer Disease

Interventions

Azeliragon; Placebo

Participants

43

Sites

33

Countries

Canada, United States

Trials that died the same way

• RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
  “Business reasons.” (83% match in meaning)
• A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
  “For Strategic Reasons” (82% match in meaning)
• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  “Due to business reasons” (78% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (76% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.